ProQR Therapeutics ( NASDAQ:PRQR – Get Free Report ) and Krystal Biotech ( NASDAQ:KRYS – Get Free Report ) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.
Valuation & Earnings This table compares ProQR Therapeutics and Krystal Biotech”s top-line revenue, earnings per share and valuation.
Get ProQR Therapeutics alerts: Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ProQR Therapeutics $18.36 million 10.67 -$47.73 million ($0.46) -4.04 Krystal Biotech $389.13 million 26.40 $204.83 million $7.98 43.48
Krystal Biotech has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Institutional and Insider Ownership 32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by...